Vismodegib (GDC-0449)

Synonyms: GDC-0449

Vismodegib (GDC-0449) is a potent, novel and specific hedgehog inhibitor with IC50 of 3 nM and also inhibits P-gp with IC50 of 3.0 μM in a cell-free assay.

Vismodegib (GDC-0449) Chemical Structure

Vismodegib (GDC-0449) Chemical Structure

CAS: 879085-55-9

Selleck's Vismodegib (GDC-0449) has been cited by 197 publications

Purity & Quality Control

Batch: Purity: 99.99%
99.99

Vismodegib (GDC-0449) Related Products

Choose Selective Hedgehog/Smoothened Inhibitors

Cell Data

Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
IGROV-1 Growth Inhibition Assay IC50=0.07248 μM SANGER
HCE-T Growth Inhibition Assay IC50=1.32247 μM SANGER
D-542MG Growth Inhibition Assay IC50=1.86737 μM SANGER
23132-87 Growth Inhibition Assay IC50=4.40147 μM SANGER
HDLM-2 Growth Inhibition Assay IC50=8.04766 μM SANGER
ACN Growth Inhibition Assay IC50=8.50109 μM SANGER
HuO-3N1 Growth Inhibition Assay IC50=9.60108 μM SANGER
BHT-101 Growth Inhibition Assay IC50=11.38 μM SANGER
KYSE-150 Growth Inhibition Assay IC50=11.5841 μM SANGER
MC-IXC Growth Inhibition Assay IC50=12.2292 μM SANGER
D-423MG Growth Inhibition Assay IC50=12.7657 μM SANGER
NY Growth Inhibition Assay IC50=14.8903 μM SANGER
HOS Growth Inhibition Assay IC50=15.6719 μM SANGER
NB7 Growth Inhibition Assay IC50=15.891 μM SANGER
DMS-273 Growth Inhibition Assay IC50=16.6713 μM SANGER
MDA-MB-361 Growth Inhibition Assay IC50=17.2711 μM SANGER
DU-145 Growth Inhibition Assay IC50=18.32 μM SANGER
NCI-H82 Growth Inhibition Assay IC50=19.8386 μM SANGER
NCI-SNU-1 Growth Inhibition Assay IC50=20.0196 μM SANGER
GCT Growth Inhibition Assay IC50=20.8824 μM SANGER
C2BBe1 Growth Inhibition Assay IC50=21.1058 μM SANGER
LB2241-RCC Growth Inhibition Assay IC50=21.8441 μM SANGER
COLO-829 Growth Inhibition Assay IC50=22.1871 μM SANGER
EW-11 Growth Inhibition Assay IC50=22.8022 μM SANGER
NCI-H526 Growth Inhibition Assay IC50=23.4717 μM SANGER
SF295 Growth Inhibition Assay IC50=24.0252 μM SANGER
D-566MG Growth Inhibition Assay IC50=25.2943 μM SANGER
8505C Growth Inhibition Assay IC50=25.6331 μM SANGER
HT-29 Growth Inhibition Assay IC50=26.0431 μM SANGER
NBsusSR Growth Inhibition Assay IC50=26.8006 μM SANGER
BV-173 Growth Inhibition Assay IC50=28.3182 μM SANGER
CTB-1 Growth Inhibition Assay IC50=30.1031 μM SANGER
JAR Growth Inhibition Assay IC50=32.5371 μM SANGER
CAMA-1 Growth Inhibition Assay IC50=33.4615 μM SANGER
CAL-51 Growth Inhibition Assay IC50=34.7176 μM SANGER
A172 Growth Inhibition Assay IC50=37.4921 μM SANGER
QIMR-WIL Growth Inhibition Assay IC50=38.0708 μM SANGER
AsPC-1 Growth Inhibition Assay IC50=38.4651 μM SANGER
MKN7 Growth Inhibition Assay IC50=39.0079 μM SANGER
ONS-76 Growth Inhibition Assay IC50=43.3057 μM SANGER
RS4-11 Growth Inhibition Assay IC50=44.0752 μM SANGER
NOS-1 Growth Inhibition Assay IC50=44.6031 μM SANGER
A101D Growth Inhibition Assay IC50=44.8023 μM SANGER
HCC1806 Growth Inhibition Assay IC50=46.1148 μM SANGER
CAL-27 Growth Inhibition Assay IC50=47.7246 μM SANGER
BT-549 Growth Inhibition Assay IC50=48.5315 μM SANGER
LCLC-97TM1 Growth Inhibition Assay IC50=49.2413 μM SANGER
A4-Fuk Growth Inhibition Assay IC50=49.849 μM SANGER
OVCAR-4 Growth Inhibition Assay IC50=50.0601 μM SANGER
HD-MY-Z Growth Inhibition Assay IC50=50.7764 μM SANGER
NCI-H292 Growth Inhibition Assay IC50=50.8758 μM SANGER
Sk-ChA-1  Growth Inhibition Assay 0.25–50 μM 72 h IC50=74.54±2.58μM 25742482
Mz-ChA-1 Growth Inhibition Assay 0.25–50 μM 72 h IC50=54.97±3.45μM 25742482
Smo-WT Growth Inhibition Assay IC50 of 14 nM 24291104
Smo-D473H  Growth Inhibition Assay IC50 of 7.1 μM 24291104
K562 Function Assay 10 μM 72 h reduces the expression of Gli1  23319824
T315I BCR-ABL BaF3 Function Assay 10 μM 72 h reduces the expression of Gli1  23319824
TF-1 BCR-ABL Function Assay 10 μM 72 h reduces the expression of Gli1  23319824
Shh-Light 2 Function assay 2 days Antagonist activity at Smo in mouse Shh-Light 2 cells assessed as inhibition of Shh-induced Gli1-reporter activity after 2 days by dual-luciferase reporter gene method, IC50 = 0.0015 μM. 23063522
NIH/3T3 Function assay Inhibition of hedgehog signaling (unknown origin) expressed in mouse NIH/3T3 cells by Gli-dual-luciferase reporter assay, IC50 = 0.0023 μM. 27180012
NIH/3T3 Light2 Function assay Inhibition of hedgehog signaling pathway in mouse NIH/3T3 Light2 cells by Gli-luciferase reporter gene assay, IC50 = 0.0023 μM. 28688278
Light2 Function assay 48 hrs Inhibition of hedgehog signaling pathway in mouse Light2 cells after 48 hrs by Gli-luciferase reporter gene assay, IC50 = 0.00246 μM. 29739714
HEPM Function assay Inhibition of SHH in human HEPM cells by Gli-luciferase reporter gene assay, INH = 0.0028 μM. 19716296
Shh Light2 Function assay Inhibition of SHH in mouse Shh Light2 cells by GLI-responsive firefly luciferase reporter gene assay, IC50 = 0.003 μM. 19309080
HEPM Function assay Inhibition of Hedgehog signaling in human HEPM cells assessed as reduction in receptor-mediated Gli1 mRNA expression by reporter gene assay, INH = 0.003 μM. 20875741
C3H10T1/2 Function assay 20 hrs Inhibition of Smo in mouse C3H10T1/2 cells using human recombinant SHH assessed as effect on SMO/SHH transient transcriptional activation after 20 hrs by Gli-luciferase reporter assay, IC50 = 0.005 μM. 24900436
NIH/3T3 Function assay 24 hrs Inhibition of hedgehog signaling pathway in mouse NIH/3T3 cells measured after 24 hrs by Gli-dual luciferase reporter gene assay, IC50 = 0.005 μM. 27810591
NIH3T3 Function assay 48 hrs Inhibition of smo-mediated hedgehog signaling pathway in mouse NIH3T3 cells expressing GRE-Luc reporter gene assessed as inhibition of SAG-induced GRE-Luc reporter activity after 48 hrs by luminescence assay, IC50 = 0.006 μM. 29499483
Shh-light2 Function assay Inhibition of Smo-mediated Hh signaling in human Shh-light2 cells by luciferase reporter gene assay, IC50 = 0.007 μM. 22268551
HEK293 Function assay 2 hrs Displacement of BODIPY-labelled cyclopamine from human Smo receptor expressed in HEK293 cells after 2 hrs by fluorescence microscopy, IC50 = 0.007 μM. 22268551
NIH3T3 Function assay Inhibition of hedgehog receptor signaling pathway in mouse NIH3T3 cells transfected with Gli-reporter gene by luciferase reporter gene assay, IC50 = 0.00717 μM. 24923765
NIH/3T3 Function assay 48 hrs Inhibition of Hedgehog signaling pathway in mouse NIH/3T3 cells assessed as reduction in Sonic hedgehog-induced Gli luciferase activity after 48 hrs by Dual-luciferase reporter gene assay, IC50 = 0.00717 μM. 30249494
NIH3T3 Function assay 48 hrs Inhibition of hedgehog signalling in mouse NIH3T3 cells stably transfected with Gli-luciferase construct incubated for 48 hrs by dual luciferase reporter gene assay, IC50 = 0.0072 μM. 26827136
NIH3T3 Function assay 48 hrs Inhibition of Sonic-induced hedgehog signalling in mouse NIH3T3 cells after 48 hrs by Gli-luciferase reporter assay, IC50 = 0.0072 μM. 26820554
NIH3T3 Function assay 48 hrs Inhibition of SHH signaling pathway in mouse NIH3T3 cells measured after 48 hrs by Gli-luciferase reporter assay, IC50 = 0.0072 μM. 24176396
NIH/3T3 Function assay 48 hrs Inhibition of hedgehog signaling pathway in mouse NIH/3T3 cells after 48 hrs by Gli-luciferase reporter gene assay, IC50 = 0.0072 μM. 24486203
NIH/3T3 Function assay Inhibition of hedgehog signaling pathway in mouse NIH/3T3 cells by Gli1-luciferase reporter gene assay, IC50 = 0.0072 μM. 24405704
NIH/3T3 Function assay Inhibition of hedgehog signaling pathway in mouse NIH/3T3 cells carrying stably transfected Gli-reporter construct by luciferase reporter assay, IC50 = 0.0072 μM. 28642101
C3H10T1/2 Function assay 6 hrs Inhibition of SAG-induced differentiation of mouse mesenchymal pluripotent C3H10T1/2 cells to alkaline phosphatase positive oeseoblasts after 6 hrs, IC50 = 0.011 μM. 22268551
HCC827 Function assay Displacement of [3H]-cyclopamine from SMO V404M mutant in gefitinib resistant human HCC827 cells by scintillation counting, Ki = 0.0122 μM. 28787156
C3H10T1/2 Function assay Inhibition of SHH in mouse C3H10T1/2 cells by Gli-luciferase reporter gene assay, IC50 = 0.013 μM. 19716296
S12 Function assay Inhibition of Hedgehog signaling in mouse S12 cells assessed as reduction in receptor-mediated Gli1 mRNA expression by reporter gene assay, INH = 0.013 μM. 20875741
TM3 Function assay 48 hrs Inhibition of Hh signaling pathway in mouse TM3 cells assessed as downregulation of Gli1 gene expression after 48 hrs by luciferase reporter gene assay, EC50 = 0.013 μM. 26976215
NIH/3T3 Function assay Inhibition of hedgehog signaling pathway in mouse NIH/3T3 cells expressing wild type Smo assessed as reduction in Gli mRNA expression by RT-PCR method, IC50 = 0.0144 μM. 27810591
S12 Function assay 48 hrs Inhibition of human SHH pathway in mouse S12 cells assessed as GLI-mediated transcriptional activity after 48 hrs by luciferase reporter gene assay, IC50 = 0.015 μM. 21438527
NIH/3T3 Function assay Inhibition of SMO in mouse NIH/3T3 cells assessed as inhibition of SAG-induced hedgehog-mediated luminescence signaling by GRE-luciferase reporter gene assay, IC50 = 0.016 μM. 26119500
U2OS Function assay 2 hrs Displacement of [3H]cyclopamine from wild type Smo expressed in U2OS cells after 2 hrs by scintillation counting, Ki = 0.0162 μM. 23063522
NIH3T3 Function assay 30 hrs Inhibition of Smo receptor (unknown origin) expressed in NIH3T3 cells assessed as inhibition of Smo agonist SAG-induced GRE activation after 30 hrs by luciferase reporter gene assay, IC50 = 0.023 μM. 24726807
medulloblastoma cell Antiproliferative assay 36 hrs Antiproliferative activity against Ptch+/- and p53-/- mouse medulloblastoma cells after 36 hrs by Brdu incorporation assay, IC50 = 0.0304 μM. 28688278
Shh Light2 Function assay Antagonist activity at smoothened (unknown origin) expressed in mouse Shh Light2 cells co-expressing Gli-dependent reporter gene assessed as inhibition of Hh signaling by dual luciferase reporter gene assay, IC50 = 0.033 μM. 24491459
Light2 Function assay Inhibition of hedgehog signaling pathway in mouse Light2 cells in Shh conditioned medium by Gli-luciferase reporter gene assay, IC50 = 0.039 μM. 28873303
Shh Light2 Function assay Inhibition of Smo-mediated Hh signalling pathway in mouse Shh Light2 cells by Gli-luciferase reporter gene assay, IC50 = 0.0392 μM. 27736063
ASZ001 Function assay 48 hrs Inhibition of Hedgehog signaling in mouse ASZ001 cells assessed as downregulation of Gli1 mRNA expression after 48 hrs by RT-PCR analysis, IC50 = 0.04 μM. 24900716
NIH/3T3 Function assay 48 hrs Antagonist activity at Smo receptor in mouse NIH/3T3 cells harboring GRE-Luc assessed as inhibition of SAG-induced Hh signaling pathway preincubated with cells followed by SAG addition measured after 48 hrs by luciferase reporter gene assay, IC50 = 0.046 μM. 29857275
Light2 Function assay 30 hrs Inhibition of hedgehog signaling pathway in mouse Light2 cells in Shh conditioned medium after 30 hrs by Gli-Renilla luciferase reporter gene assay, IC50 = 0.05 μM. 30099257
C3H10T1/2 Function assay 6 days Inhibition of hedgehog signaling pathway-mediated differentiation of mouse C3H10T1/2 cells assessed as decrease in SAG-induced ALP activity after 6 days by chemiluminescence-based assay, IC50 = 0.05 μM. 30099257
DaOY Function assay 48 hrs Inhibition of Hedgehog signaling in human DaOY cells assessed as downregulation of Gli1 mRNA expression after 48 hrs by RT-PCR analysis, IC50 = 0.086 μM. 24900716
C3H10T1/2 Function assay 1 hr Inhibition of Hedgehog signaling pathway in mouse C3H10T1/2 cells assessed as reduction in purmorphamine-induced increase in alkaline phosphatase level using CDP-star as substrate pretreated for 1 hr followed by purmorphamine addition measured after 5 day, IC50 = 0.14 μM. 28947939
M210B4 Function assay 24 hrs Inhibition of Hedgehog signaling in mouse M210B4 cells assessed as downregulation of Ptch mRNA expression after 24 hrs by RT-PCR analysis, IC50 = 0.14 μM. 24900716
M210B4 Function assay 24 hrs Inhibition of Hedgehog signaling in mouse M210B4 cells assessed as downregulation of Gli1 mRNA expression after 24 hrs by RT-PCR analysis, IC50 = 0.2 μM. 24900716
Shh Light2 Function assay 1 hr Inhibition of Hedgehog signaling in mouse Shh Light2 cells assessed as reduction in purmorphamine-induced Gli mediated transcriptional activity pretreated for 1 hr followed by purmorphamine addition measured after 48 hrs by luciferase reporter gene assay, IC50 = 0.98 μM. 28947939
NIH/3T3 Function assay Inhibition of hedgehog signaling pathway in mouse NIH/3T3 cells harboring Smo D477H mutant assessed as reduction in Gli mRNA expression by RT-PCR method, IC50 = 1.196 μM. 27810591
S12 Function assay 48 hrs Inhibition of human SHH pathway in mouse S12 cells assessed as GLI-mediated transcriptional activity after 48 hrs by luciferase reporter gene assay in presence of 0.5 mg/mL human alpha-1-acid glycoprotein, IC50 = 1.75 μM. 21438527
Calu6 Function assay 4 hrs Plasma concentration in human Calu6 cells xenografted in nude mouse at 75 mg/kg, po bid measured after 4 hrs post fifth dose, Cp = 23 μM. 19716296
Calu-6 Function assay Plasma concentration in Calu-6 cells xenografted nude mouse PK/PD model at 75 mg/kg, po bid for 5 days measured 4 hrs post last dose relative to untreated control, Cp = 23 μM. 20875741
T47D Cytotoxicity assay 72 hrs Cytotoxicity against human T47D cells after 72 hrs by MTT assay, IC50 = 41.34 μM. 29107429
LS180 Antiproliferative assay 72 hrs Antiproliferative activity against human LS180 cells after 72 hrs by sulforhodamine-B assay, IC50 = 45 μM. 30099257
LS174T Antiproliferative assay 72 hrs Antiproliferative activity against human LS174T cells after 72 hrs by CellTiter-Glo luminescent cell viability assay, IC50 = 45.81 μM. 26820554
BxPC3 Antiproliferative assay 72 hrs Antiproliferative activity against human BxPC3 cells after 72 hrs by CellTiter-Glo luminescent cell viability assay, IC50 = 47.95 μM. 26820554
medulloblastoma cell Antitumor assay Antitumor activity against mouse medulloblastoma cells xenografted in Ptch +/- mouse assessed as decrease in tumor volume at 12.5 mg/kg, po bid. 19716296
S12 Function assay 48 hrs Inhibition of human SHH pathway in mouse S12 cells assessed as GLI-mediated transcriptional activity after 48 hrs by luciferase reporter gene assay in presence of 1 mg/mL human alpha-1-acid glycoprotein. 21438527
Shh Light2 Function assay 0.1 uM 36 hrs Inhibition of Smo-mediated Hh signalling pathway in mouse Shh Light2 cells assessed as suppression of Gli1-mRNA expression at 0.1 uM measured after 36 hrs by RT-qPCR analysis. 27736063
SW1353 Antiproliferative assay 10 uM 48 hrs Antiproliferative activity against human SW1353 cells assessed as growth inhibition at 10 uM after 48 hrs by MTT assay. 24491459
DaOY Antiproliferative assay 10 uM 48 hrs Antiproliferative activity against human DaOY cells assessed as growth inhibition at 10 uM after 48 hrs by MTT assay. 24491459
A549 Antiproliferative assay 10 uM 48 hrs Antiproliferative activity against human A549 cells assessed as growth inhibition at 10 uM after 48 hrs by MTT assay. 24491459
HCT116 Antiproliferative assay 10 uM 48 hrs Antiproliferative activity against human HCT116 cells assessed as growth inhibition at 10 uM after 48 hrs by MTT assay. 24491459
NIH/3T3 Function assay 10 uM Inhibition of Hedgehog signaling in mouse NIH/3T3 cells assessed as down regulation of mPTCH1 mRNA expression at 10 uM. 24491459
MSC Function assay 20 to 80 uM Inhibition of hedgehog signaling in mouse MSC cells assessed as down regulation of alkaline phosphatase at 20 to 80 uM. 24491459
SK-N-MC qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells. 29435139
TC32 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells. 29435139
NIH3T3-Luc Function assay 1 uM 48 hrs Inhibition of smo-mediated hedgehog signaling pathway in mouse NIH3T3-Luc cells assessed as downregulation of Gli mRNA expression at 1 uM after 48 hrs by real-time PCR analysis. 29499483
C3H10T1/2 Function assay 24 hrs Inhibition of hedgehog signaling pathway-mediated GLI1 mRNA expression in mouse C3H10T1/2 cells after 24 hrs by RT-PCR analysis in presence of (1R,3aR,4S,7aR)-7a-methyl-1-((R)-6-methylheptan-2-yl)octahydro-1H-inden-4-yl 3-hydroxybenzoate. 24730984
C3H10T1/2 Function assay 24 hrs Inhibition of hedgehog signaling pathway-mediated GLI1 mRNA expression in mouse C3H10T1/2 cells after 24 hrs by RT-PCR analysis in presence of VD3. 24730984
NIH/3T3 Function assay 100 nM 36 hrs Inhibition of hedgehog signaling pathway in mouse NIH/3T3 cells assessed as downregulation of Shh-induced Gli1 mRNA expression levels at 100 nM after 36 hrs by RT-qPCR analysis. 28873303
C3H10T1/2 Function assay 100 nM 36 hrs Inhibition of hedgehog signaling pathway in mouse C3H10T1/2 cells assessed as downregulation of Shh-induced Gli1 mRNA expression levels at 100 nM after 36 hrs by RT-qPCR analysis. 28873303
NIH/3T3 Function assay 100 nM 36 hrs Inhibition of hedgehog signaling pathway in mouse NIH/3T3 cells assessed as downregulation of Shh-induced ptch1 mRNA expression levels at 100 nM after 36 hrs by RT-qPCR analysis. 28873303
C3H10T1/2 Function assay 100 nM 36 hrs Inhibition of hedgehog signaling pathway in mouse C3H10T1/2 cells assessed as downregulation of Shh-induced ptch1 mRNA expression levels at 100 nM after 36 hrs by RT-qPCR analysis. 28873303
medulloblastoma cell Antiproliferative assay up to 30 uM 72 hrs Antiproliferative activity against mouse Ptch+/- p53-/- medulloblastoma cells assessed as reduction in cell proliferation up to 30 uM after 72 hrs by MTS assay. 28873303
medulloblastoma cell Apoptosis assay Induction of apoptosis in mouse Ptch+/- p53-/- medulloblastoma cells implanted in athymic nude mouse at 12.5 mg/kg, ip bid for 15 consecutive days by TUNEL assay. 28873303
NIH/3T3 Function assay Inhibition of hedgehog signaling pathway expressed in mouse NIH/3T3 cells assessed as inhibition of hedgehog-induced Gli-2 accumulation at tip of primary cilia by DAPI staining based confocal microscopic analysis. 27810591
NIH/3T3 Function assay Inhibition of hedgehog signaling pathway in mouse NIH/3T3 cells assessed as inhibition of hedgehog-induced Smo-EGFP ciliary translocation by DAPI staining based confocal microscopic analysis. 27810591
medulloblastoma cell Anti-tumor assay Anti-tumor activity against mouse Ptch+/- p53-/- medulloblastoma cells implanted in athymic nude mouse assessed as tumor growth inhibition at 20 mg/kg, po administered twice daily via gavage measured every other day during compound dosing. 29739714
C3H10T1/2 Function assay 4.1 to 1000 nM Allosteric inhibition of Smo in mouse C3H10T1/2 cells assessed as inhibition of purmorphamine-induced Gli1 transcriptional activity at 4.1 to 1000 nM by qPCr analysis. 23074541
C3H10T1/2 Function assay 4.1 to 1000 nM Competitive inhibition of Smo in mouse C3H10T1/2 cells assessed as inhibition of SAG-induced Gli1 transcriptional activity at 4.1 to 1000 nM by qPCR analysis. 23074541
Click to View More Cell Line Experimental Data

Biological Activity

Description Vismodegib (GDC-0449) is a potent, novel and specific hedgehog inhibitor with IC50 of 3 nM and also inhibits P-gp with IC50 of 3.0 μM in a cell-free assay.
Targets
Hedgehog [1]
(Cell-free assay)
3 nM
In vitro
In vitro GDC-0449 targets the Hedgehog signaling pathway, blocking the activities of the Hedgehog-ligand cell surface receptors PTCH and/or SMO and suppressing Hedgehog signaling. GDC-0449 prevents multiple ATP-binding cassette (ABC) transporters. GDC-0449 also blocks ABCG2, Pgp, and MRP1-important ABC transporters associated with MDR. GDC-0449 is a potent inhibitor of ABC transporters, ABCG2/BCRP and ABCB1/Pgp, and is a mild inhibitor of ABCC1/MRP1. In ABCG2-overexpressing HEK293 cells, GDC-0449 increases retention of the fluorescent ABCG2 substrate BODIPY-prazosin and resensitizes these cells to mitoxantrone. In Madin-Darby canine kidney II cells engineered to overexpress Pgp or MRP1, GDC-0449 increases the retention of calcein-AM and resensitizes them to colchicine. GDC-0449 also resensitizes human non-small cell lung carcinoma cells NCI-H460/par and NCI-H460/MX20, which overexpress ABCG2 in response to mitoxantrone, to mitoxantrone, and to topotecan or SN-38. The IC50 values of GDC-0449 for prevention of ABCG2 and Pgp are about 1.4 μM and 3.0 μM, respectively. [2] GDC-0449 alters intracellular Ca2+ homeostasis and inhibits cell growth in cisplatin-resistant lung cancer cells. [3]
Cell Research Cell lines MDCKII cells
Concentrations 20 μM
Incubation Time 2 hours
Method MDCKII cells are seeded into 24-well plates at a density of 3 × 105 cells per well and are allowed to attach. Medium is then changed to that containing different drugs (50 μM VP, 50 μM indomethacin, or 20 μM GDC-0449 in DMSO or DMSO alone as control, and nonfluorescent calcein-AM is added to a final concentration of 1.0 μM and incubated at 37 °C for 2 hours. Cells are then washed twice with Ca2+, Mg2+-containing Hank's balanced salt solution buffer and lysed by shaking in 0.01% Triton X-100 in PBS buffer for 1 hour at room temperature or overnight at 4 °C. The lysate is then transferred into 96-well plates, and the fluorescence signal caused by the cell-derived calcein is quantified spectrophotometrically with a SpectraMax M5 Multi-Detection Readerusing an excitation wavelength of 495 nm and an emission wavelength of 515 nm. All manipulations are performed in the dark. All readings are expressed as mean ?SEM normalized to the control.
Experimental Result Images Methods Biomarkers Images PMID
Western blot Fas / DR4 / DR5 / Cleaved PARP / Bcl-2 / Cleaved caspase-3 / PDGFRα p-GSK3β / GSK3β / p-Akt / Akt / Gli1 Gli1 / SOX2 / OCT4 p53 / Cyclin D1 / p21 Bcl-2 / Bax 22087285
Immunofluorescence Gli1 / Gli2 22087285
Growth inhibition assay Cell viability 29042665
In Vivo
In vivo GDC-0449 has been used to treat medulloblastoma in animal models. [2] GDC-0449 prevents the growth of primary pancreatic xenografts without non-specifically inhibiting pancreatic cell proliferation. Oral dosing of GDC-0449 causes tumor regressions in the Ptch(+/-) allograft model of medulloblastoma at doses ≥25 mg/kg and tumor growth inhibition at doses up to 92 mg/kg dosed twice daily in two ligand-dependent colorectal cancer models, D5123, and 1040830. Analysis of Hh pathway activity and PK/PD modeling reveals that GDC-0449 inhibits Gli1 with a similar IC50 in both the medulloblastoma and D5123 models (0.165 μM and 0.267 μM, respectively). Pathway modulation is linked to efficacy using an integrated PK/PD model revealing a steep relationship where > 50% of the activity of GDC-0449 is associated with >80% repression of the Hh pathway. [4]
Animal Research Animal Models Ptch(+/-) allograft model, D5123 and 1040830
Dosages ~ 100 mg/kg
Administration Orally
NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03610022 Completed
Metastatic Basal Cell Carcinoma|Locally Advanced Basal Cell Carcinoma
University Hospital Bordeaux
September 3 2018 Phase 4
NCT03035188 Completed
Basal Cell Carcinoma
SRH Wald-Klinikum Gera GmbH
January 2017 Phase 2
NCT02781389 Completed
Basal Cell Carcinoma
University Hospital Essen|OnkoDataMed GmbH
April 29 2016 --
NCT02593760 Completed
Myelofibrosis
Hoffmann-La Roche
January 25 2016 Phase 1
NCT02648048 Completed
Idiopathic Pulmonary Fibrosis
Hoffmann-La Roche
January 15 2016 Phase 1
NCT02436408 Completed
Carcinoma Basal Cell
University of Michigan Rogel Cancer Center
July 15 2015 Phase 4

Chemical Information & Solubility

Molecular Weight 421.3 Formula

C19H14Cl2N2O3S

CAS No. 879085-55-9 SDF Download Vismodegib (GDC-0449) SDF
Smiles CS(=O)(=O)C1=CC(=C(C=C1)C(=O)NC2=CC(=C(C=C2)Cl)C3=CC=CC=N3)Cl
Storage (From the date of receipt)

In vitro
Batch:

DMSO : 84 mg/mL ( (199.38 mM); Moisture-absorbing DMSO reduces solubility. Please use fresh DMSO.)

Water : Insoluble

Ethanol : Insoluble


Molecular Weight Calculator

In vivo
Batch:

Add solvents to the product individually and in order.


In vivo Formulation Calculator

Preparing Stock Solutions

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Vismodegib (GDC-0449) | Vismodegib (GDC-0449) supplier | purchase Vismodegib (GDC-0449) | Vismodegib (GDC-0449) cost | Vismodegib (GDC-0449) manufacturer | order Vismodegib (GDC-0449) | Vismodegib (GDC-0449) distributor